Yasuo Nakagishi Selected Research

Macrophage Activation Syndrome

1/2021	Comparison of serum cytokine profiles in macrophage activation syndrome complicating different background rheumatic diseases in children.
12/2020	Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis during tocilizumab therapy.
1/2020	Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
11/2019	Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
11/2019	Extensive serum biomarker analysis in patients with macrophage activation syndrome associated with systemic lupus erythematosus.
1/2019	Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome.
7/2016	Successful therapy of macrophage activation syndrome with dexamethasone palmitate.
4/2016	Disruption of vascular endothelial homeostasis in systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The dynamic roles of angiopoietin-1 and -2.
10/2015	Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
5/2012	Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yasuo Nakagishi Research Topics

Disease

18	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 01/2021 - 05/2012
10	Macrophage Activation Syndrome 01/2021 - 05/2012
5	Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) 01/2021 - 01/2015
4	Arthritis (Polyarthritis) 04/2019 - 02/2013
2	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 12/2020 - 04/2016
2	Fever (Fevers) 12/2020 - 01/2020
2	Infections 01/2019 - 05/2012
2	Disease Progression 01/2009 - 10/2008
1	Nerve Compression Syndromes (Nerve Entrapment) 01/2022
1	Rheumatic Diseases (Rheumatism) 01/2021
1	Multi-centric Castleman's Disease 12/2020
1	Sepsis (Septicemia) 01/2020
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 11/2019
1	Uveitis 04/2019
1	Human Influenza (Influenza) 01/2019
1	Inflammation (Inflammations) 07/2016
1	Vasculitis (Vasculitides) 10/2008
1	Anemia 10/2008
1	Microaneurysm 10/2008
1	Infarction (Infarctions) 10/2008
1	Polyarteritis Nodosa (Periarteritis Nodosa) 10/2008
1	Hypergammaglobulinemia (Hyperimmunoglobulinemia) 06/2007

Drug/Important Bio-Agent (IBA)

8	Interleukin-18 (Interleukin 18)IBA 01/2021 - 05/2012
8	Biomarkers (Surrogate Marker)IBA 01/2021 - 09/2017
5	CytokinesIBA 01/2021 - 02/2013
4	Interleukin-6 (Interleukin 6)IBA 01/2021 - 05/2012
4	tocilizumab (atlizumab)FDA Link 12/2020 - 05/2012
4	InterleukinsIBA 09/2017 - 02/2013
3	C-Reactive ProteinIBA 04/2019 - 06/2007
2	SteroidsIBA 12/2020 - 04/2019
2	Ferritins (Ferritin)IBA 01/2020 - 11/2016
2	Indicators and Reagents (Reagents)IBA 01/2020 - 07/2017
2	Biological ProductsIBA 04/2019 - 09/2018
2	Leucine (L-Leucine)FDA Link 01/2019 - 09/2017
1	NeopterinIBA 01/2021
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2021
1	Rituximab (Mabthera)FDA Link 12/2020
1	Interferon-gamma (Interferon, gamma)IBA 01/2020
1	Abatacept (Orencia)FDA Link 04/2019
1	AntibodiesIBA 04/2019
1	Adalimumab (Humira)FDA Link 04/2019
1	Infliximab (Remicade)FDA Link 04/2019
1	Methotrexate (Mexate)FDA LinkGeneric 04/2019
1	Ophthalmic Solutions (Eye Drops)IBA 04/2019
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 09/2017
1	Interleukin-33IBA 07/2017
1	Rheumatoid FactorIBA 07/2017
1	Dexamethasone (Maxidex)FDA LinkGeneric 07/2016
1	Methylprednisolone FDA LinkGeneric 07/2016
1	PalmitatesIBA 07/2016
1	AngiopoietinsIBA 04/2016
1	Angiopoietin-1IBA 04/2016
1	Mevalonic Acid (Mevalonate)IBA 01/2009
1	Simvastatin (Zocor)FDA LinkGeneric 01/2009
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2008
1	beta 2-Microglobulin (beta 2 Microglobulin)IBA 10/2008
1	fibrinmonomerIBA 10/2008
1	formycin diphosphate (FDP)IBA 10/2008
1	InterferonsIBA 10/2008
1	Prednisolone (Predate)FDA LinkGeneric 10/2008
1	fibrin fragment D (D-dimer)IBA 10/2008

Therapy/Procedure

5	Therapeutics 12/2020 - 10/2008
1	Conservative Treatment 01/2022